참고문헌
- Awakura Y, Ito N, Nakamura E, et al (2006). Matrix metalloproteinase-9 polymorphisms and renal cell carcinoma in a Japanese population. Cancer Lett, 241, 59-63. https://doi.org/10.1016/j.canlet.2005.10.005
- Barbui T, Barosi G, Birgegard G, et al (2011). Philadelphianegative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol, 29, 761-70. https://doi.org/10.1200/JCO.2010.31.8436
- Bayramoglu A, Urhan Kucuk M, Guler HI, et al (2013). Is there any genetic predisposition of MMP-9 gene C1562T and MTHFR gene C677T polymorphisms with essential hypertension? Cytotechnology, Nov 21. [Epub ahead of print]
- Besses C, Cervantes F, Pereira A, et al (1999). Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia, 13, 150-4. https://doi.org/10.1038/sj.leu.2401270
- Buggins AG, Levi A, Gohil S, et al (2011). Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol, 154, 216-22. https://doi.org/10.1111/j.1365-2141.2011.08725.x
- Dameshek W (1951). Some speculations on the myeloproliferative syndromes. Blood, 6, 372-5.
- Decock J, Paridaens R, Ye S (2008). Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin Genet, 73, 197-211.
- Egeblad M, Werb Z (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer, 2, 161-74. https://doi.org/10.1038/nrc745
- Ennis BW, Matrisian LM (1994). Matrix degrading metalloproteinases. J Neuro Oncol, 18, 105-9. https://doi.org/10.1007/BF01050416
- Gentner B, Wein A, Croner RS, et al (2009). Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases. Anticancer Res, 29, 67-74.
- Gruppo Italiano Studio Policitemia (1995). Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med, 123, 656-64. https://doi.org/10.7326/0003-4819-123-9-199511010-00003
- Guo XT, Wang JF, Zhang LY, Xu GQ (2012). Quantitative assessment of the effects of MMP-2 polymorphisms on lung carcinoma risk. Asian Pac J Cancer Prev, 13, 2853-6. https://doi.org/10.7314/APJCP.2012.13.6.2853
- Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C (2008). The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol, 87, 1-10.
- Harendza S, Lovett DH, Panzer U, et al (2003). Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem, 278, 20490-9. https://doi.org/10.1074/jbc.M211536200
- Hewitt R, Dan K (1996). Stromal cell expression of components of matrixdegrading protease systems in human cancer. Enzyme Protein, 49, 163-73.
- Hu C, Wang J, Xu Y, et al (2013). Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: a meta-analysis. Gene, 517, 65-71. https://doi.org/10.1016/j.gene.2012.12.085
- Kaushansky K (2006). Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders. Cytokine Growth Factor Rev, 17, 423-30. https://doi.org/10.1016/j.cytogfr.2006.09.005
- Kuittinen O, Savolainen ER, Koistinen P, Mottonen M, Turpeenniemi-Hujanen T (2001). MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL). Leuk Res, 25, 125-31. https://doi.org/10.1016/S0145-2126(00)00104-1
- Lacchini R, Jacob-Ferreira AL, Luizon MR, et al (2012). Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J Hum Hypertens, 26, 171-7. https://doi.org/10.1038/jhh.2011.8
- Lane WJ, Dias S, Hattori K, et al (2000). Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood, 96, 4152-9.
- Langers AM, Sier CF, Hawinkels LJ, et al (2008). MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not. Br J Cancer, 98, 820-3.
- Li LN, Zhou X, Gu Y, Yan J (2013). Prognostic value of MMP-9 in ovarian cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 4107-13. https://doi.org/10.7314/APJCP.2013.14.7.4107
- Li Y, Jin X, Kang S, et al (2006). Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Gynecol Oncol, 101, 92-6. https://doi.org/10.1016/j.ygyno.2005.09.058
- Majka M, Janowska-Wieczorek A, Ratajczak J, et al (2000). Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. Blood, 96, 4142-51.
- Malaponte G, Polesel J, Candido S, et al (2013). IL-6-174 G > C and MMP-9-1562 C>T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients. Cytokine, 62, 64-9. https://doi.org/10.1016/j.cyto.2013.02.017
- Marchioli R, Finazzi G, Landolfi R, et al (2005). Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol, 23, 2224-32. https://doi.org/10.1200/JCO.2005.07.062
- Marquez-Curtis LA, Dobrowsky A, Montano J, et al (2001). Matrix metalloproteinase and tissue inhibitors of metalloproteinase secretion by haematopoietic and stromal precursors and their production in normal and leukaemic long-term marrow cultures. Br J Haematol, 115, 595-604. https://doi.org/10.1046/j.1365-2141.2001.03160.x
- Matrisian LM (1990). Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet, 6, 121-5. https://doi.org/10.1016/0168-9525(90)90126-Q
- Mehtap O, Atesoglu EB, Tarkun P, et al (2012). The association between gene polymorphisms and leukocytosis with thrombotic complications in patients with essential thrombocythemia and polycythemia vera. Turk J Haematol, 29, 162-9. https://doi.org/10.5505/tjh.2012.03780
- Ogawa M, Kawamoto M, Yamanaka N (2000). Matrix metalloproteinase and tissue inhibitor of metalloproteinase in human bone marrow tissues-an immunohistochemical study. J Nippon Med Sch, 67, 235-41. https://doi.org/10.1272/jnms.67.235
- Palei AC, Sandrim VC, Amaral LM, et al (2012). Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J, 12, 489-98. https://doi.org/10.1038/tpj.2011.31
- Park KS, Kim SJ, Kim KH, Kim JC (2011). Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol, 26, 391-7. https://doi.org/10.1111/j.1440-1746.2010.06504.x
- Payandeh M, Zadeh FS, Zare ME, et al (2011). Evalution of common genetic disorders in myeloproliferative neoplasms. IJHOSCR, 5, 16-20.
- Pereza N, Ostojic S, Volk M, Kapovic M, Peterlin B (2012). Matrix metalloproteinases 1, 2, 3 and 9 functional single-nucleotide polymorphisms in idiopathic recurrent spontaneous abortion. Reprod Biomed Online, 24, 567-75. https://doi.org/10.1016/j.rbmo.2012.01.008
- Price SJ, Greaves DR, Watkins H (2000). Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene:role of Sp1 in allele-specific transcriptional regulation. J Biol Chem, 276, 7549-58.
- Rollin J, Regina S, Vourc'h P, et al (2007). Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer, 56, 273-80. https://doi.org/10.1016/j.lungcan.2006.11.021
- Saeed HM, Alanazi MS, Parine NR, et al (2013). Matrix metalloproteinase-2 (-1306 c>t) promoter polymorphism and risk of colorectal cancer in the Saudi population. Asian Pac J Cancer Prev, 14, 6025-30. https://doi.org/10.7314/APJCP.2013.14.10.6025
- Sanii S, Saffar H, Tabriz HM, et al (2012). Expression of matrix metalloproteinase-2, but not caspase-3, facilitates distinction between benign and malignant thyroid follicular neoplasms. Asian Pac J Cancer Prev, 13, 2175-8. https://doi.org/10.7314/APJCP.2012.13.5.2175
- Scott LM (2013). Lymphoid malignancies: another face to the Janus kinases. Blood Rev, 27, 63-70. https://doi.org/10.1016/j.blre.2012.12.004
- Sfar S, Saad H, Mosbah F, Gabbouj S, Chouchane L (2007). TSP1 and MMP9 genetic variants in sporadic prostate cancer. Cancer Genet Cytogenet, 172, 38-44. https://doi.org/10.1016/j.cancergencyto.2006.07.014
- Srivastava P, Kapoor R, Mittal RD (2013). Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India. Urol Oncol, 31, 247-54. https://doi.org/10.1016/j.urolonc.2011.01.001
- Soriano G, Heaney M (2013). Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications. Curr Opin Hematol, 20, 169-75. https://doi.org/10.1097/MOH.0b013e32835d82fe
- Sugimoto M, Yoshida S, Kennedy S, et al (2006). Matrix metalloproteinase-1 and -9 promoter polymorphisms and endometrial carcinoma risk in a Japanese population. J Soc Gynecol Investig, 13, 523-9.
- Szczudlik P, Borratynska A (2010). Association between the-1562 C/T MMP-9 polymorphism and cerebrovascular disease in a Polish population. Neurol Neurochir Pol, 44, 350-7.
- Tefferi A, Vainchenker W (2011). Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol, 29, 573-82. https://doi.org/10.1200/JCO.2010.29.8711
- Thorgeirsson UP, Lindsay CK, Cottam DW, Gomez DE (1994). Tumor invasion, proteolysis and angiogenesis. J Neuro Oncol, 18, 89-103. https://doi.org/10.1007/BF01050415
- Travaglino E, Benatti C, Malcovati L, et al (2008). Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. Eur J Haematol, 80, 216-26. https://doi.org/10.1111/j.1600-0609.2007.01012.x
- Vairaktaris E, Vassiliou S, Nkenke E, et al (2008). A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol, 34, 450-5. https://doi.org/10.1016/j.ejso.2007.03.024
- Vasku A, Goldbergova M, Izakovicova Holla L, et al (2004). A haplotype constituted of four MMP-2 promoter polymorphisms (-1575G/A, -1306C/T, -790T/G and -735C/T) is associated with coronary triple-vessel disease. Matrix Biol, 22, 585-91. https://doi.org/10.1016/j.matbio.2003.10.004
- Wadleigh M, Tefferi A (2010). Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol, 91, 174-9. https://doi.org/10.1007/s12185-010-0529-5
- Wagenaar-Miller RA, Gorden L, Matrisian LM (2004). Matrix metalloproteinases in colorectal cancer: is it worth talking about?. Cancer Metastasis Rev, 23, 119-35. https://doi.org/10.1023/A:1025819214508
- Wang J, Warzecha D, Wilcken D, Wang XL (2001). Polymorphism in the gelatinase B gene and the severity of coronary arterial stenosis. Clin Sci (Lond), 101, 87-92. https://doi.org/10.1042/CS20000317
- Wang Y, Fang S, Wei L, et al (2005). No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma. Lung Cancer, 49, 155-61. https://doi.org/10.1016/j.lungcan.2005.04.006
- Woo M, Park K, Nam J, Kim JC (2007). Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol, 22, 1064-70. https://doi.org/10.1111/j.1440-1746.2006.04424.x
- Wu CY, Wu MS, Chen YJ, et al (2007). Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer. Eur J Cancer, 43, 799-808. https://doi.org/10.1016/j.ejca.2006.10.022
- Xiaoping M, YuAC (2003). Functional polymorphism in the matrix metalloproteinase-2 gene promoter (1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res, 63, 3987-90.
- Yang TF, Guo L, Wang Q (2014). Meta-analysis of associations between four polymorphisms in the matrix metalloproteinases gene and gastric cancer risk. Asian Pac J Cancer Prev, 15, 1263-7. https://doi.org/10.7314/APJCP.2014.15.3.1263
- Yari K, Rahimi Z, Moradi MT, Rahimi Z (2014). The MMP-2-735 C allele is a risk factor for susceptibility to breast cancer. Asian Pac J Cancer Prev, 15, 6199-203. https://doi.org/10.7314/APJCP.2014.15.15.6199
- Yu C, Zhou Y, Miao X, et al (2004). Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res, 64, 7622-8. https://doi.org/10.1158/0008-5472.CAN-04-1521
- Yu XF, Han ZC (2006). Matrix metalloproteinases in bone marrow: roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies. Histol Histopathol, 21, 519-31.
- Zhang B, Ye S, Herrmann SM, et al (1999). Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation, 99, 1788-94. https://doi.org/10.1161/01.CIR.99.14.1788
- Zhang B, Henney A, Eriksson P, et al (1999). Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet, 105, 418-23. https://doi.org/10.1007/s004390051124
- Zhou Y, Yu C, Miao X, et al (2005). Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis, 26, 1117-21. https://doi.org/10.1093/carcin/bgi057
피인용 문헌
- Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.5013
- Acquired JAK-2 V617F Mutational Analysis in Pakistani Patients with Essential Thrombocythemia vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.7327
- Clinico-Hematological Profile and Risk Stratification in Patients with Essential Thrombocythemia: Experience from Pakistan vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7659
- JAK-2 V617F Mutational Analysis in Primary Idiopathic Myelofibrosis: Experience from Southern Pakistan vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7889
- Primary Idiopathic Myelofibrosis: Clinico-Epidemiological Profile and Risk Stratification in Pakistani Patients vol.16, pp.18, 2016, https://doi.org/10.7314/APJCP.2015.16.18.8629
- Somatic JAK-2 V617F Mutational Analysis in Polycythemia Rubra Vera: a Tertiary Care Center Experience vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1053
- Clinico-Epidemiological Profile of Patients with Polycythaemia Rubra Vera - a Five Year Experience from a Tertiary Care Center vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1531